Many techniques for studying functional genomics of important target sites of anthelmintics have been restricted to Caenorhabditis elegans because they have failed when applied to animal parasites. To overcome these limitations, we have focused our research on the human nematode parasite Brugia malayi, which causes elephantiasis. Here, we combine single-cell PCR, whole muscle cell patch clamp, motility phenotyping (Worminator), and dsRNA for RNAi for functional genomic studies that have revealed, in vivo, four different muscle nAChRs (M-, L-, P-, and N-). The cholinergic anthelmintics had different selectivities for these receptors. We show that motility and patch-clamp responses to levamisole and pyrantel, but not morantel or nicotine, require the unc-38 and/or unc-29 genes. Derquantel behaved as a competitive antagonist and distinguished M-nAChRs activated by morantel (K b 13.9 nM), P-nAChRs activated by pyrantel (K b 126 nM), and L-nAChRs activated by levamisole (K b 0.96 μM) and bephenium. Derquantel was a noncompetitive antagonist of nicotine, revealing N-type nAChRs. The presence of four diverse nAChRs on muscle is perhaps surprising and not predicted from the C. elegans model. The diverse nAChRs represent distinguishable drug targets with different functions: Knockdown of unc-38+unc-29 (L-and/or P-receptors) inhibited motility but knockdown of acr-16+acr-26 (M-and/or N-receptors) did not.T he neglected tropical diseases caused by nematode parasites affect some 2 billion people globally, and effective vaccines are not available. Although these parasites by themselves do not produce high mortality, they produce significant morbidity that affects worker productivity and increase susceptibility to AIDS and malaria, and they are strongly associated with poverty in endemic countries (1-4). There are only a limited number of classes of anthelmintic drugs that are used to treat these diseases, and there are concerns about the development of resistance (5). There is a pressing need to advance the study of anthelmintic drugs.Many useful studies on modes of action of anthelmintic drugs have been conducted on the model nematode, Caenorhabditis elegans, but this is not a parasite: It is separated evolutionarily by millions of years from parasitic nematodes and it does not possess "parasitism genes" (6). This separation increases the impetus for anthelmintic studies using real parasites, but until now many techniques developed in C. elegans have not have been tractable when applied to animal parasites (7).The neuromuscular systems of nematodes, which control motility and support feeding, growth, and reproduction, are governed by significant parts of their gene pools (8, 9). Their neuromuscular systems are unlike those of vertebrates because nematode muscles send processes to the motor neurons to form synapses, rather than the other way around. Membrane ion-channels, which regulate nematode neuromuscular systems, are target sites of major classes of anthelmintic drugs, including the cholinergic anthelmintics levamisole,...